4//SEC Filing
Hopkins Leo Nelson 4
Accession 0001209191-10-047749
CIK 0001028318other
Filed
Sep 27, 8:00 PM ET
Accepted
Sep 28, 6:11 PM ET
Size
17.3 KB
Accession
0001209191-10-047749
Insider Transaction Report
Form 4
Hopkins Leo Nelson
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$5.72/sh−10,000$57,200→ 0 totalExercise: $17.68Exp: 2016-11-14→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$5.89/sh−10,000$58,900→ 0 totalExercise: $17.51Exp: 2017-11-12→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$10.56/sh−10,000$105,600→ 0 totalExercise: $12.84Exp: 2018-09-16→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$9.94/sh−10,000$99,400→ 0 totalExercise: $13.46Exp: 2019-09-15→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$22.64/sh−526$11,906→ 0 totalExercise: $0.77Exp: 2013-06-24→ Common Stock (526 underlying) - Disposition to Issuer
Common Stock
2010-09-27−1,500→ 0 total(indirect: By LLC)
Footnotes (3)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of July 11, 2010, between Micrus Endovascular Corporation, Johnson & Johnson and Cope Acquisition Corp., each share of common stock held by the reporting person was converted into the right to receive $23.40 in cash, without interest.
- [F2]The reporting shares are owned directly by Delphi Venture Partners, LLC ("Delphi") a limited liability company. The reporting person holds less than a 10% interest of Delphi and is a co-manager of Delphi. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F3]Pursuant to the Agreement and Plan of Merger, dated as of July 11, 2010, between Micrus Endovascular Corporation, Johnson & Johnson and Cope Acquisition Corp., this stock option was converted into the right to receive an amount in cash per share subject to the stock option equal to the excess of the per share merger consideration of $23.40 over the per share exercise price of each stock option, without interest.
Documents
Issuer
MICRUS ENDOVASCULAR CORP
CIK 0001028318
Entity typeother
Related Parties
1- filerCIK 0001326410
Filing Metadata
- Form type
- 4
- Filed
- Sep 27, 8:00 PM ET
- Accepted
- Sep 28, 6:11 PM ET
- Size
- 17.3 KB